Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Actelion    ATLN   CH0010532478

ACTELION (ATLN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Managers
NameAgeSinceTitle
Ludo Ooms-2017Chairman
Julian Bertschinger-2017Director
Claudio Cescato-2017Director
Pascal Hoorn-2017Director
Andrea Ostinelli-2010Director
Marian Borovsky, LLD482000Secretary, Senior VP & Group General Counsel
Nicholas Franco, MBA552011Chief Business Development Officer & Executive VP
Christian Albrich, MBA532002Senior VP & Head-Global Human Resources
Peter Herrmann--Head-Compliance & Corporate Affairs
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 107,329,410 2,009,425 1.9% 4,654,225 4.3% 1.9%
Markets and indexes
- SIX Swiss Exchange
- Main Standard
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  ATLN.S
- Datastream Code :  
Company contact information
Actelion
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ACTELION27.10%0
GILEAD SCIENCES1.16%94 196
REGENERON PHARMACEUTICALS6.67%41 388
VERTEX PHARMACEUTICALS100.10%36 580
GENMAB4.43%11 537
EXELIXIS, INC.76.93%7 589
BLUEBIRD BIO INC164.51%7 580
JUNO THERAPEUTICS INC211.09%6 743
NEUROCRINE BIOSCIENCES, INC.86.77%6 351
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.7.11%6 151
BIOVERATIV INC0.00%5 492
TESARO INC-36.12%4 543
ADAPTIMMUNE THERAPEUTICS PLC - ADR94.57%4 413
HUALAN BIOLOGICAL ENGINEERING INC--.--%4 182
BIOCON LTD24.28%3 904
PEPTIDREAM INC-40.21%3 880
SAREPTA THERAPEUTICS INC104.56%3 634
BEIGENE LTD (ADR)177.27%3 597
BEIJING SL PHARMACEUTICAL CO LTD--.--%3 578
CLOVIS ONCOLOGY INC42.30%3 131
AVEXIS INC103.81%3 066
Connections : Actelion
Actelion US Holding Co.
Actelion Production Ltd.
Actelion Pharma Schweiz AG
Echo-Sense, Inc.
Actelion Pharmaceuticals Canada, Inc.
Actelion Pharmaceuticals Korea Ltd.
Actelion Pharmaceuticals CZ sro
Swiss Bar Association
Actelion Pharmaceuticals SK Sro
Actelion Pharmaceuticals Japan Ltd.
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem